|
299 | 299 | "description": "Evidence pertaining to biomarkers associated with FDA-approved therapies or professional guidelines for this tumour type", |
300 | 300 | "displayName": "IPR-A", |
301 | 301 | "links": [ |
| 302 | + { |
| 303 | + "class": "CrossReferenceOf", |
| 304 | + "source": "ipr", |
| 305 | + "target": "cgi-cpic guidelines" |
| 306 | + }, |
302 | 307 | { |
303 | 308 | "class": "CrossReferenceOf", |
304 | 309 | "source": "ipr", |
|
725 | 730 | }, |
726 | 731 | "moa-inferential": { |
727 | 732 | "displayName": "MOAlmanac Inferential", |
728 | | - "links": [ |
729 | | - { |
730 | | - "class": "CrossReferenceOf", |
731 | | - "target": "civic-e1" |
732 | | - }, |
733 | | - { |
734 | | - "class": "CrossReferenceOf", |
735 | | - "target": "civic-e2" |
736 | | - }, |
737 | | - { |
738 | | - "class": "CrossReferenceOf", |
739 | | - "target": "civic-e3" |
740 | | - }, |
741 | | - { |
742 | | - "class": "CrossReferenceOf", |
743 | | - "target": "civic-e4" |
744 | | - }, |
745 | | - { |
746 | | - "class": "CrossReferenceOf", |
747 | | - "target": "civic-e5" |
748 | | - }, |
749 | | - { |
750 | | - "class": "CrossReferenceOf", |
751 | | - "target": "profyle-t5" |
752 | | - } |
753 | | - ], |
754 | 733 | "name": "Inferential", |
755 | 734 | "source": "moa", |
756 | 735 | "sourceId": "Inferential" |
|
909 | 888 | "profyle-t2": { |
910 | 889 | "description": "Biomarkers that predict response or resistance to therapies based on well-powered clinical trials", |
911 | 890 | "displayName": "PROFYLE T2", |
912 | | - "links": [ |
913 | | - { |
914 | | - "class": "CrossReferenceOf", |
915 | | - "target": "profyle-t2a" |
916 | | - }, |
917 | | - { |
918 | | - "class": "CrossReferenceOf", |
919 | | - "target": "profyle-t2b" |
920 | | - } |
921 | | - ], |
922 | 891 | "name": "PROFYLE Therapeutic Level 2", |
923 | 892 | "source": "profyle", |
924 | 893 | "sourceId": "T2" |
|
942 | 911 | "profyle-t3": { |
943 | 912 | "description": "Biomarkers that predict response or resistance to therapies based on small series, case-reports, or that serve as inclusion criteria for a clinical trial", |
944 | 913 | "displayName": "PROFYLE T3", |
945 | | - "links": [ |
946 | | - { |
947 | | - "class": "CrossReferenceOf", |
948 | | - "target": "profyle-t3a" |
949 | | - }, |
950 | | - { |
951 | | - "class": "CrossReferenceOf", |
952 | | - "target": "profyle-t3b" |
953 | | - } |
954 | | - ], |
955 | 914 | "name": "PROFYLE Therapeutic Level 3", |
956 | 915 | "source": "profyle", |
957 | 916 | "sourceId": "T3" |
|
975 | 934 | "profyle-t4": { |
976 | 935 | "description": "Biomarkers that show plausible therapeutic significance based on preclinical studies", |
977 | 936 | "displayName": "PROFYLE T4", |
978 | | - "links": [ |
979 | | - { |
980 | | - "class": "CrossReferenceOf", |
981 | | - "target": "profyle-t4a" |
982 | | - }, |
983 | | - { |
984 | | - "class": "CrossReferenceOf", |
985 | | - "target": "profyle-t4b" |
986 | | - } |
987 | | - ], |
988 | 937 | "name": "PROFYLE Therapeutic Level 4", |
989 | 938 | "preclinical": true, |
990 | 939 | "source": "profyle", |
|
1011 | 960 | "profyle-t5": { |
1012 | 961 | "description": "Novel biomarkers predicted to be oncogenic in therapeutically actionable genes, or evidence of activation of a therapeutically actionable pathway", |
1013 | 962 | "displayName": "PROFYLE T5", |
1014 | | - "links": [ |
1015 | | - { |
1016 | | - "class": "CrossReferenceOf", |
1017 | | - "target": "profyle-t5a" |
1018 | | - }, |
1019 | | - { |
1020 | | - "class": "CrossReferenceOf", |
1021 | | - "target": "profyle-t5b" |
1022 | | - } |
1023 | | - ], |
1024 | 963 | "name": "PROFYLE Therapeutic Level 5", |
1025 | 964 | "source": "profyle", |
1026 | 965 | "sourceId": "T5" |
|
0 commit comments